{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:46:38Z","timestamp":1787996798125,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11912-021-01126-7","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T09:25:47Z","timestamp":1637313947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early Progressing Follicular Lymphoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Danielle","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"1126_CR1","unstructured":"National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: NPCR and SEER Incidence. In: United States Department of Health and Human Services CfDCaPaNCI, editor.2019."},{"issue":"1","key":"1126_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107(1):265\u201376. https:\/\/doi.org\/10.1182\/blood-2005-06-2508.","journal-title":"Blood"},{"issue":"10","key":"1126_CR3","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1172\/jci63186","volume":"122","author":"R Kridel","year":"2012","unstructured":"Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424\u201331. https:\/\/doi.org\/10.1172\/jci63186.","journal-title":"J Clin Invest"},{"issue":"31","key":"1126_CR4","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/jco.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848\u201353. https:\/\/doi.org\/10.1200\/jco.2010.33.4474.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1126_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/jco.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322. https:\/\/doi.org\/10.1200\/jco.2014.59.7534.","journal-title":"J Clin Oncol"},{"issue":"9873","key":"1126_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(12)61763-2.","journal-title":"Lancet"},{"issue":"9759","key":"1126_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(10)62175-7.","journal-title":"Lancet"},{"issue":"11","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096\u2013101. https:\/\/doi.org\/10.1002\/ajh.24492.","journal-title":"Am J Hematol"},{"key":"1126_CR9","doi-asserted-by":"publisher","unstructured":"Casulo C, Le-Rademacher J, Dixon J, Salles G, Hoster E, Herold M et al. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 Clinical Trials. Blood. 2017;130(Supplement 1):412-. doi:https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.412.412.","DOI":"10.1182\/blood.V130.Suppl_1.412.412"},{"issue":"7","key":"1126_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","volume":"99","author":"C Sortais","year":"2020","unstructured":"Sortais C, Lok A, Tessoulin B, Gastinne T, Mah\u00e9 B, Dubruille V, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99(7):1595\u2013604. https:\/\/doi.org\/10.1007\/s00277-020-04025-2.","journal-title":"Ann Hematol"},{"key":"1126_CR11","doi-asserted-by":"publisher","unstructured":"Launonen A, Hiddemann W, Duenzinger U, Fingerle-Rowson G, Nielsen T, Marcus R. Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study. Blood. 2017;130(Supplement 1):1490-. doi:https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.1490.1490.","DOI":"10.1182\/blood.V130.Suppl_1.1490.1490"},{"issue":"6","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"FS John","year":"2019","unstructured":"John FS, Robert M, Andrew D, Eve G-E, Andrew G, Andrew H, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202\u20138. https:\/\/doi.org\/10.3324\/haematol.2018.209015.","journal-title":"Haematologica"},{"issue":"19","key":"1126_CR13","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944\u201352. https:\/\/doi.org\/10.1182\/blood-2013-11-531327.","journal-title":"Blood"},{"key":"1126_CR14","doi-asserted-by":"publisher","unstructured":"Winter AM, Nastoupil LJ, Becnel MR, Cerhan JR, Habermann TM, Link BK et al. Outcomes of follicular lymphoma patients treated with frontline bendamustine and rituximab: impact of histologic grade and early progression on overall survival. Blood. 2018;132(Supplement 1):4146-. doi:https:\/\/doi.org\/10.1182\/blood-2018-99-118530.","DOI":"10.1182\/blood-2018-99-118530"},{"issue":"9","key":"1126_CR15","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134(9):761\u20134. https:\/\/doi.org\/10.1182\/blood.2019000258.","journal-title":"Blood"},{"issue":"5","key":"1126_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365. https:\/\/doi.org\/10.1182\/blood-2003-12-4434.","journal-title":"Blood"},{"issue":"27","key":"1126_CR17","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/jco.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362. https:\/\/doi.org\/10.1200\/jco.2008.21.3991.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1126_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112\u201320. https:\/\/doi.org\/10.1182\/blood-2016-05-717355.","journal-title":"Blood"},{"issue":"5","key":"1126_CR19","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108(5):1504\u20138. https:\/\/doi.org\/10.1182\/blood-2006-01-013367.","journal-title":"Blood"},{"issue":"1","key":"1126_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405.","journal-title":"Blood"},{"issue":"S2","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/hon.2437_85","volume":"35","author":"S Huet","year":"2017","unstructured":"Huet S, Szafer-Glusman E, Xerri L, Bolen C, Punnoose E, Tonon L, et al. Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial. Hematol Oncol. 2017;35(S2):96\u20137. https:\/\/doi.org\/10.1002\/hon.2437_85.","journal-title":"Hematol Oncol"},{"issue":"12","key":"1126_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ajh.25973","volume":"95","author":"F Mir","year":"2020","unstructured":"Mir F, Mattiello F, Grigg A, Herold M, Hiddemann W, Marcus R, et al. Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol. 2020;95(12):1503\u201310. https:\/\/doi.org\/10.1002\/ajh.25973.","journal-title":"Am J Hematol"},{"issue":"21","key":"1126_CR23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159\u201369. https:\/\/doi.org\/10.1056\/NEJMoa041869.","journal-title":"N Engl J Med"},{"issue":"4","key":"1126_CR24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549\u201361. https:\/\/doi.org\/10.1016\/s1470-2045(18)30102-5.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/s1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(15)00169-2.","journal-title":"Lancet Oncol"},{"issue":"14","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1614598.","journal-title":"N Engl J Med"},{"key":"1126_CR27","doi-asserted-by":"publisher","unstructured":"Jurinovic V, Passerini V, Oestergaard MZ, Knapp A, Mundt K, Araf S et al. Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood. 2019;134(Supplement_1):122-. doi:https:\/\/doi.org\/10.1182\/blood-2019-130208.","DOI":"10.1182\/blood-2019-130208"},{"issue":"2","key":"1126_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/bjh.16159","volume":"188","author":"S Lockmer","year":"2020","unstructured":"Lockmer S, Ren W, Brodtkorb M, \u00d8stenstad B, Wahlin BE, Pan-Hammarstr\u00f6m Q, et al. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol. 2020;188(2):259\u201367. https:\/\/doi.org\/10.1111\/bjh.16159.","journal-title":"Br J Haematol"},{"issue":"34","key":"1126_CR29","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1200\/jco.18.02365","volume":"37","author":"JWD Tobin","year":"2019","unstructured":"Tobin JWD, Keane C, Gunawardana J, Mollee P, Birch S, Hoang T, et al. Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. J Clin Oncol. 2019;37(34):3300\u20139. https:\/\/doi.org\/10.1200\/jco.18.02365.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1126_CR30","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/jco.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, et al. Sustained Progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815\u201324. https:\/\/doi.org\/10.1200\/jco.19.01073.","journal-title":"J Clin Oncol"},{"key":"1126_CR31","doi-asserted-by":"publisher","unstructured":"Prochazka VK, Belada D, Janikova A, Benesova K, Mocikova H, Duras J et al. Early follicular lymphoma progression in patients treated with frontline immunochemotherapy with\/without rituximab maintenance: clinically meaningful even in chemosensitive individuals. Blood. 2019;134(Supplement_1):3983-. doi:https:\/\/doi.org\/10.1182\/blood-2019-129756.","DOI":"10.1182\/blood-2019-129756"},{"issue":"6","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202\u20138. https:\/\/doi.org\/10.3324\/haematol.2018.209015.","journal-title":"Haematologica"},{"issue":"22","key":"1126_CR33","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/jco.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575\u201382. https:\/\/doi.org\/10.1200\/jco.2015.65.7163.","journal-title":"J Clin Oncol"},{"key":"1126_CR34","doi-asserted-by":"publisher","unstructured":"Link BK, Day B-m, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. British Journal of Haematology. 2019;184(4):660\u20133. doi:https:\/\/doi.org\/10.1111\/bjh.15149.","DOI":"10.1111\/bjh.15149"},{"issue":"10","key":"1126_CR35","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.bbmt.2017.05.021","volume":"23","author":"A Jim\u00e9nez-Ubieto","year":"2017","unstructured":"Jim\u00e9nez-Ubieto A, Grande C, Caballero D, Y\u00e1\u00f1ez L, Novelli S, Hern\u00e1ndez-Garcia MT, et al. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017;23(10):1631\u201340. https:\/\/doi.org\/10.1016\/j.bbmt.2017.05.021.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"1126_CR36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/hon.2553","volume":"36","author":"A Jim\u00e9nez-Ubieto","year":"2018","unstructured":"Jim\u00e9nez-Ubieto A, Grande C, Caballero D, Y\u00e1\u00f1ez L, Novelli S, Hern\u00e1ndez-Garcia MT, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol. 2018;36(5):765\u201372. https:\/\/doi.org\/10.1002\/hon.2553.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1126_CR37","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163\u201371. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.771.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1126_CR38","doi-asserted-by":"publisher","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Peschel C et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma- retrospective analysis of 2 randomized trials of the German low grade lymphoma study group (GLSG). Blood. 2016;128(22):3464-. doi:https:\/\/doi.org\/10.1182\/blood.V128.22.3464.3464.","DOI":"10.1182\/blood.V128.22.3464.3464"},{"issue":"1","key":"1126_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/10428194.2018.1473576","volume":"60","author":"M Manna","year":"2019","unstructured":"Manna M, Lee-Ying R, Davies G, Stewart C, Oh DH, Peters A, et al. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma. 2019;60(1):133\u201341. https:\/\/doi.org\/10.1080\/10428194.2018.1473576.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1126_CR40","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cncr.31374","volume":"124","author":"SM Smith","year":"2018","unstructured":"Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018;124(12):2541\u201351. https:\/\/doi.org\/10.1002\/cncr.31374.","journal-title":"Cancer"},{"issue":"8","key":"1126_CR41","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.31264","volume":"124","author":"A Sureda","year":"2018","unstructured":"Sureda A, Zhang M-J, Dreger P, Carreras J, Fenske T, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer. 2018;124(8):1733\u201342. https:\/\/doi.org\/10.1002\/cncr.31264.","journal-title":"Cancer"},{"issue":"8","key":"1126_CR42","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081\u201393. https:\/\/doi.org\/10.1016\/s1470-2045(16)30097-3.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1126_CR43","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/jco.2017.76.3656","volume":"36","author":"BD Cheson","year":"2018","unstructured":"Cheson BD, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259\u201366. https:\/\/doi.org\/10.1200\/jco.2017.76.3656.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1126_CR44","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/s2352-3026(19)30089-4","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6(8):e429\u201337. https:\/\/doi.org\/10.1016\/s2352-3026(19)30089-4.","journal-title":"Lancet Haematol"},{"key":"1126_CR45","doi-asserted-by":"publisher","unstructured":"Andorsky DJ, Coleman M, Yacoub A, Melear JM, Fanning SR, Kolibaba K et al. MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma. Journal of Clinical Oncology. 2019;37(15_suppl):7513-. doi:https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.7513.","DOI":"10.1200\/JCO.2019.37.15_suppl.7513"},{"key":"1126_CR46","doi-asserted-by":"publisher","unstructured":"Andorsky DJ, Yacoub A, Melear JM, Coleman M, Kolibaba KS, Brooks HD et al. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed\/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). Journal of Clinical Oncology. 2017;35(15_suppl):7502-. doi:https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.7502.","DOI":"10.1200\/JCO.2017.35.15_suppl.7502"},{"key":"1126_CR47","doi-asserted-by":"publisher","unstructured":"Andorsky DJ, Coleman M, Yacoub A, Melear JM, Fanning SR, Kolibaba KS et al. MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent NHL. Journal of Clinical Oncology. 2020;38(15_suppl):8046-. doi:https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8046.","DOI":"10.1200\/JCO.2020.38.15_suppl.8046"},{"issue":"11","key":"1126_CR48","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1314583.","journal-title":"N Engl J Med"},{"issue":"22","key":"1126_CR49","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","volume":"129","author":"AK Gopal","year":"2017","unstructured":"Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, et al. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129(22):3037\u20139. https:\/\/doi.org\/10.1182\/blood-2016-12-757740.","journal-title":"Blood"},{"issue":"35","key":"1126_CR50","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/jco.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898\u2013905. https:\/\/doi.org\/10.1200\/jco.2017.75.4648.","journal-title":"J Clin Oncol"},{"key":"1126_CR51","doi-asserted-by":"publisher","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows GA, Lenz G et al. Long-term efficacy and safety from the copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma. Blood. 2018;132(Supplement 1):1595-. doi:https:\/\/doi.org\/10.1182\/blood-2018-99-114842.","DOI":"10.1182\/blood-2018-99-114842"},{"issue":"11","key":"1126_CR52","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/ajh.25228","volume":"93","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, et al. Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018;93(11):1311\u20137. https:\/\/doi.org\/10.1002\/ajh.25228.","journal-title":"Am J Hematol"},{"issue":"11","key":"1126_CR53","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912\u201322. https:\/\/doi.org\/10.1200\/JCO.18.00915.","journal-title":"J Clin Oncol"},{"key":"1126_CR54","unstructured":"TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed\/Refractory Follicular Lymphoma [press release]. New York: TG Therapeutics, Inc. https:\/\/bit.ly\/2JOU8Yn. Accessed 12\/2\/2020."},{"issue":"11","key":"1126_CR55","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/s1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(20)30441-1.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"1126_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-135839","volume":"136","author":"SE Assouline","year":"2020","unstructured":"Assouline SE, Kim WS, Sehn LH, Schuster SJ, Cheah CY, Nastoupil LJ, et al. Mosunetuzumab Shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial. Blood. 2020;136(Supplement 1):42\u20134. https:\/\/doi.org\/10.1182\/blood-2020-135839.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1126_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-136834","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL). Blood. 2020;136(Supplement 1):40\u20131. https:\/\/doi.org\/10.1182\/blood-2020-136834.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-021-01126-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T10:23:06Z","timestamp":1638354186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-021-01126-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s11912-021-01126-7","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"29 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"D.W reports that they have no conflicts of interest that might be relevant to the contents of this manuscript. C.C reports research funding from Verastem, Gilead, BMS and Genentech\/Roche.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"149"}}